A single-species approach considering additional physiological information for prediction of hepatic clearance of glycoprotein derivate therapeutics
- PMID: 21895038
- DOI: 10.2165/11592610-000000000-00000
A single-species approach considering additional physiological information for prediction of hepatic clearance of glycoprotein derivate therapeutics
Abstract
Background and objectives: Existing methods for the prediction of human clearance of therapeutic proteins involve the use of allometry approaches. In general, these approaches have concentrated on the role of body weight, with only occasional attention given to more specific physiological parameters. The objective of this study was to develop a mechanism-based model of hepatic clearance (CL(H)), which combines a single-species scaling approach with liver physiology, for predicting CL(H) of selected glycoprotein derivate therapeutics, and to compare the outcome of this novel method with those of two empirical methods obtained from the literature - namely, the single-exponent theory and multiple-species allometry. Thus, this study was designed as an explanatory study to verify if the addition of physiological information is of benefit for extrapolating clearance of selected therapeutic proteins from one species to another.
Methods: Five glycoprotein derivate therapeutics that are known to be principally eliminated by asialoglycoprotein receptors (ASGPRs) under in vivo conditions were selected. It was assumed that the interspecies differences in CL(H) reported for these compounds are reflected by the interspecies differences in the abundance of these receptors. Therefore, key scaling factors related to these differences were integrated into one model. Fourteen extrapolation (prediction) scenarios across species were used in this study while comparing the single-species model, based on physiology, with the single-exponent theory. In addition, the physiological model was compared with multiple-species allometry for three proteins.
Results: In general, the novel physiological model is superior to the derived allometric methods. Overall, the physiological model produced a predicted CL(H) value with levels of accuracy of 100% within 3-fold, 100% within 2-fold and about 82% within 1.5-fold, compared with the observed values, whereas the levels of accuracy decreased to 93%, 77% and 53%, respectively, for allometry. The proposed physiological model is also superior to allometry on the basis of the root mean square error and absolute average fold error values.
Conclusions: It has been demonstrated that interspecies differences in the abundance of ASGPRs principally govern interspecies variations in CL(H) of compounds that are principally eliminated by ASGPRs. Overall, the proposed physiological model is an additional tool, which should facilitate investigation and prediction of human CL(H) of specific glycoproteins solely on the basis of clearance data determined in a single preclinical species.
Similar articles
-
Prediction of human pharmacokinetics--evaluation of methods for prediction of hepatic metabolic clearance.J Pharm Pharmacol. 2007 Jun;59(6):803-28. doi: 10.1211/jpp.59.6.0007. J Pharm Pharmacol. 2007. PMID: 17637173
-
Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches.Pharm Res. 2005 Jan;22(1):103-12. doi: 10.1007/s11095-004-9015-1. Pharm Res. 2005. PMID: 15771236
-
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.J Pharm Sci. 2011 Oct;100(10):4090-110. doi: 10.1002/jps.22552. Epub 2011 May 3. J Pharm Sci. 2011. PMID: 21541938
-
Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations.Clin Pharmacokinet. 1999 Mar;36(3):211-31. doi: 10.2165/00003088-199936030-00003. Clin Pharmacokinet. 1999. PMID: 10223169 Review.
-
The pharmacokinetic principles behind scaling from preclinical results to phase I protocols.Clin Pharmacokinet. 1999 Jan;36(1):1-11. doi: 10.2165/00003088-199936010-00001. Clin Pharmacokinet. 1999. PMID: 9989339 Review.
Cited by
-
Comparative pharmacology of a new recombinant FSH expressed by a human cell line.Endocr Connect. 2017 Jul;6(5):297-305. doi: 10.1530/EC-17-0067. Epub 2017 Apr 27. Endocr Connect. 2017. PMID: 28450423 Free PMC article.
-
New Human Follitropin Preparations: How Glycan Structural Differences May Affect Biochemical and Biological Function and Clinical Effect.Front Endocrinol (Lausanne). 2021 Mar 19;12:636038. doi: 10.3389/fendo.2021.636038. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33815292 Free PMC article. Review.
-
Follicle-Stimulating Hormone Biological Products: Does Potency Predict Clinical Efficacy?Int J Mol Sci. 2023 May 19;24(10):9020. doi: 10.3390/ijms24109020. Int J Mol Sci. 2023. PMID: 37240364 Free PMC article. Review.
-
Knowledge Gaps in the Pharmacokinetics of Therapeutic Proteins in Pediatric Patients.Front Pharmacol. 2022 Feb 10;13:847021. doi: 10.3389/fphar.2022.847021. eCollection 2022. Front Pharmacol. 2022. PMID: 35222051 Free PMC article.
-
Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.Clin Pharmacokinet. 2016 Jul;55(7):789-805. doi: 10.1007/s40262-015-0361-4. Clin Pharmacokinet. 2016. PMID: 26818483 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources